New York-based Applied Therapeutics develops treatments for cardio-metabolic conditions. Its drug, AT-007, is being developed to treat galactosemia, a rare condition diagnosed at birth that affects how the body breaks down galactose, a sugar produced in the body and found in lactose, the sugar present in milk. It's estimated to impact one of every 30,000 to 60,000 newborns. Beyond galactosemia, Applied is also working on two other compounds, including one for diabetic cardiomyopathy, a complication from diabetes that results in a thickening of the heart muscle, and diabetic retinopathy, another diabetes complication that affects the eye.

The hope is to use the drugs to inhibit an enzyme called aldose reductase, responsible for breaking down sugars into chemicals that aren't good for our bodies — in the case of galactosemia, that's a sugar alcohol known as galactitol and in diabetic patients breaking down glucose incorrectly, that ends up being a sugar alcohol known as sorbitol. Aldose reductase has been a validated drug target for more than 25 years. Pharmaceutical companies developed a number of these aldose reductase inhibitors in the 1990s, but the drugs didn't pan out, often because of side effects. But now, using technology licensed in from Columbia University, the hope is to circumvent those side effects. Overall, indications involving aldose reductase activation are linked to hundreds of millions of patients worldwide.


Click is a diagnostic company developing single-use, disposable diagnostic cartridges.  The company’s initial product will be indicated for three sexually transmitted infections (STIs), for which there are over 50 million tests each year.  The company’s near-term mission is to provide physicians with patient-side diagnostic test results that enable accurate and immediate treatment.  Through dramatic miniaturization and cost reduction of polymerase chain reaction (PCR) technology, the company has produced a disposable diagnostic device that is easy-to-use, inexpensive, and, importantly, rapid.  Whereas most diagnostic tests are generally sent from the physician’s office to a dedicated laboratory testing center, requiring days to receive results, Click’s cartridge efficiently displays colorimetric results after inputting a sample into the device.  In the long-term, the company’s goal is to revolutionize the diagnostics industry by making molecular testing readily accessible.


Picket Pharmaceuticals develops and brings to market innovative complex generic pharmaceutical products across a range of therapeutic areas. The company’s team leverages their experience in clinical trials and regulatory affairs in the area of drug product development. Working within FDA guidance documents and the 505(b)2 regulatory pathway to select appropriate therapeutic areas, Picket strives to swiftly and cost effectively provide affordable medications for patients where lack of generic products limits access to treatment. The company also has capabilities with BLA (biologics license application) and NCE (new chemical entities) partnership developments. Picket is focused on choosing the right drug candidates, formulation, designing and executing BE study.


Radformation is an oncology software company that develops radiation oncology workflow solutions and integrates with state-of-the-art radiation equipment. As medical physicists in a cancer clinic, the company’s founders experienced the frustrations of manually putting together complex treatment plans for patients. The founders leveraged their experiences to develop FDA 510(k) cleared software that allows cancer clinics to catch errors quickly at the source and automate generation of high-quality treatment plans faster than current manual methods allow. The company helps clinics provide patients with optimal treatments and avoid patient harm. The company’s software is compatible with a multitude of cancer treatment sites, and generates optimal treatment plans in minutes, expediting a process that previously required hours.


Stimwave is a medical device company developing innovative therapies for chronic pain relief.  The company’s devices treat chronic pain in the back, legs, and peripheral joints – for which prevalence in the US is over 50 million Americans and worldwide is over 400 million people.  These implanted devices are wireless, powered by a small controller attached to the interior of any article of clothing, which allows the devices to utilize microtechnology, such that they are 95% smaller than any other available neuromodulation technology – a technology which has been validated as being safe and effective over the last 40 years but had yet to experience innovation in the way this company has delivered it. 


Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. It has combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables it to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than its competitors.

The synthetic biology market is growing due to increased access to affordable and innovative tools that combine advanced production technology with modern digital technology and software capabilities, such as Twist’s DNA synthesis platform. The company is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sample preparation, and antibody libraries for drug discovery and development. Additionally, its platform will enable new value-add opportunities, such as discovery partnerships for biologic drugs, and will enable new applications for synthetic DNA, such as digital data storage, which will drive growth in the market for Twist’s products.



JUUL Labs was co-founded by two former cigarette smokers, Adam Bowen and James Monsees. They first created a company called Ploom while they were product-design grad students at Stanford University, and later created the Pax vaporizer device for cannabis and loose-leaf tobacco before founding JUUL. The JUUL electronic cigarette was introduced by PAX Labs in June 2015. In July 2017, JUUL was spun out of PAX Labs as an independent company.

JUUL’s mission has been to replace cigarettes as “the smoking alternative” and, with its advertising and marketing, as well as superior product quality, as its major competitive advantages, JUUL now accounts for over 70% of the US e-cigarette market. As the popularity of the JUUL e-cigarette has taken off, the company has grown quickly, from employing 200 people in September 2017 to 400 in May 2018 to 800 by September 2018 and over 1,500 as of 2019. The popularity and growth is epitomized by the December 2018 investment by Altria, acquiring a stake in JUUL at a roughly $38B valuation.


PAX Labs is an award-winning, consumer technology brand that supports responsible, adult use of premium cannabis vaporization technologies and devices. Headquartered in San Francisco, PAX Labs has revolutionized the industry through innovation and product design. The company boasts an exceptional team with hardware and software backgrounds in consumer technology, healthcare, and biotech. PAX Labs has sold over one million PAX devices in the flower vaporizer category and introduced PAX Era, a connected, app-driven pod system for concentrates, in September 2016.

With each consecutive model, Pax continues to innovative. The Pax 2 included the following changes: no moving parts to maintain, smaller and lighter, larger oven, and longer battery life. Pax 2 can be used with loose-leaf tobacco or cannabis. Following this, the Pax 3 was released, featuring compatibility with both extracts and plant matter, new tools and accessories, and a complementary smart phone app.



Green Growth Brands is a lifestyle oriented, consumer products company that celebrates health, wellness, and happiness.

The company brings together a collection of retailers, scientists, botanists, developers, artists and business leaders, all of whom possess a high level of hands-on expertise in their respective fields. Together, they bring a wealth of experience to product manufacturing and packaging, creating retail opportunities in stores and digital, with top-notch store training and distribution, all at speed and scale.

The founding partners and retail management team have the most retail experience compared to any other cannabis company in the world. They’ve helped to build and lead retail brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, and DSW, that have performed in the top 5% of an extremely competitive retail industry.


Tilray is pioneering the future of medical cannabis research, cultivation, processing and distribution globally and intends to become a leader in the adult-use cannabis market in Canada. Tilray has supplied high-quality cannabis products to tens of thousands of patients in 10 countries spanning five continents through subsidiaries in Australia, Canada and Germany and through agreements with established pharmaceutical distributors, and produces medical cannabis in Canada and Europe. The company is led by a team of visionary entrepreneurs, experienced operators and cannabis industry experts as well as PhD scientists, horticulturists and extraction specialists who apply the latest scientific knowledge and technology to deliver quality-controlled, rigorously tested cannabis products on a large scale.

The company has been an early leader in the development of the global medical cannabis market. It was one of the first companies to be licensed by Health Canada to cultivate and sell medical cannabis in Canada, and also one of the first companies to become a licensed dealer of medical cannabis in Canada. The cannabis industry is rapidly expanding in Canada, with more than 100 other companies that are currently licensed and hundreds more applications for licenses that are being processed by Health Canada. The company expects to have a competitive advantage in the Canadian adult-use market following the implementation of federal legislation that legalized adult-use cannabis in Canada in October 2018.